Primary small bowel adenocarcinoma: current view on clinical features, risk and prognostic factors, treatment and outcome.

Gustaw Lech, Wojciech Korcz, Emilia Kowalczyk, Robert Słotwiński, Maciej Słodkowski

Journal: Scandinavian journal of gastroenterology 2018;52(11):1194-1202

PMID: 28737049

Abstract

Small bowel adenocarcinoma (SBA) is a rare but increasing cause of gastrointestinal malignancy, being both a diagnostic and therapeutic challenge. The goal of treatment is margin negative resection of a lesion and local lymphadenectomy, followed by modern adjuvant chemotherapy combinations in selected cases. Improved outcomes in patients with SBA are encouraging, but elucidation of mechanisms of carcinogenesis and risk factors as well as improved treatment for this malignancy is very needed.

Address: a Department of General, Gastroenterological and Oncological Surgery , Medical University of Warsaw , Warsaw , Poland.; b Department of Surgical Research and Transplantology , Polish Academy of Sciences, Mossakowski Medical Research Centre , Warsaw , Poland.; c Department of Immunology, Biochemistry and Nutrition , Medical University of Warsaw , Warsaw , Poland.

DOI: 10.1080/00365521.2017.1356932

Link outs

Free resources

Medical:

https://medlineplus.gov/intestinalcancer.html

Other Literature Sources:

https://scite.ai/reports/28737049

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.1080/00365521.2...

MeSH Terms: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Carcinogenesis, Chemotherapy, Adjuvant, Digestive System Surgical Procedures, Double-Balloon Enteroscopy, Duodenal Neoplasms, Early Diagnosis, Humans, Ileal Neoplasms, Intestine, Small, Jejunal Neoplasms, Lymph Node Excision, Prognosis, Risk Factors, Treatment Outcome